Publisher's Synopsis
Anticoagulants provides authoritative reviews of proteins C and S, antithrombin III, and the recently described tissue factor pathway inhibitor. There are extensive discussions of pathologic anticoagulants, such as those found in patients with congenital clotting factor deficiencies or those that arise de novo in previously well individuals. Detailed clinical advice is presented for the management of patients with these inhibitors. A chapter on "lupus" anticoagulants provides a comprehensive review of the pathophysiology of these intriguing antibodies. Current guidelines are offered for the use of heparin, warfarin, and thrombolytic agents. The biochemistry, physiology, and clinical applications of the new, low molecular weight heparins are explored.
